PT - JOURNAL ARTICLE AU - Min Chul Choi AU - Myong Cheol Lim AU - Maria Lee AU - Min Kyu Kim AU - Dong Hoon Suh AU - Yong Jung Song AU - Tae-Joong Kim AU - Suk-Joon Chang AU - Jae-Weon Kim TI - Practice Patterns of Hereditary Ovarian Cancer Management in Korea AID - 10.1097/IGC.0000000000000964 DP - 2017 Jun 01 TA - International Journal of Gynecologic Cancer PG - 895--899 VI - 27 IP - 5 4099 - http://ijgc.bmj.com/content/27/5/895.short 4100 - http://ijgc.bmj.com/content/27/5/895.full SO - Int J Gynecol Cancer2017 Jun 01; 27 AB - Objective This study aims to evaluate practice patterns for managing hereditary ovarian cancer among Korean gynecologic oncologic physicians.Methods Members of the Korean Society of Gynecologic Oncology participated in the inaugural Hereditary Gynecologic Cancer Symposium or were invited to this survey by e-mail from January to February 2016. The survey was conducted using a self-administered questionnaire.Results Most physicians (66.7%, 36/54) responded to draw a pedigree of patients with a family history. The rate of genetic test recommendations for patients at risk for ovarian cancer was high (96.3%, 52/54). Physicians tended to select appropriate candidates for the genetic test. Of the respondents, genetic counseling was commonly performed before the genetic test (76.6%, 36/47) and provided by the specialist consultant(s) (78.7%, 37/47) or the physician alone (12.8%, 6/47). Participants showed mature response to risk management for the BRCA carriers: at least annual gynecologic surveillance (89.4%, 42/47), recommendation for chemoprevention (76.6%, 36/47), and advice for risk-reducing salpingo-oophorectomy (85.1%, 40/47). Risk-reducing salpingectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy was considered to recommend in most of respondents (91.5%, 43/47).Conclusions Gynecologic oncologic physicians in Korea had high awareness to genetic risk assessment, candidate selection to genetic test, and risk-reducing strategies for the management of hereditary ovarian cancer.